Recent Updates
Recently added Catalysts

Vertex Pharmaceuticals Incorporated

VRTXFDA catalysts, PDUFA dates & pipeline intelligence
$534.2
▼ -3.59 · -0.67%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Quarterly Cash
Unlock full VRTX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $412.2752W HIGH $568.67
Volume
1.51 M
Value Traded
807.28 M
Short % Float
1.9%
Days to Cover
3.4
-2.35%Week
+6.42%1 Month
-3.24%3 Month
+24.11%6 Month
+99.97%5 Year
+9,556%All Time

Cash Data

Unlock VRTX cash position
  • Cash FlowProfitable
  • SEC Filing

Key Stats

Market Cap
135.44 B
EPS (TTM)
15.68
P/E Ratio
34.07
Ent. Value
130.12 B
Total Shares
253.54 M
Float Shares
252.96 M
Insiders
0.23%
Institutions
98.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
povetacicept
adults with IgA nephropathy (IgAN)
PDUFABiologicsNephrology
Unlock every VRTX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

VRTX Catalyst Timeline

Dated clinical, regulatory and corporate events for Vertex Pharmaceuticals Incorporated

Catalyst Timeline

Dated clinical, regulatory & corporate events for Vertex Pharmaceuticals Incorporated

469Total events
20Upcoming
176Tier-1 (high impact)
2020 to 2027Coverage

Upcoming catalysts 2

T1PDUFA Date
Subscribe to view catalyst details
PovetaciceptFiled
T2Enrollment Complete
Subscribe to view catalyst details
SuzetrigineApproved

Event history 50

●Quarterly UpdateCorporate
Vertex reports Q3 2026 financial results with total revenue of $3.44 billion
▲Oral PresentationPovetaciceptFiledPresentation
Phase 3 RAINIER results for povetacicept presented at American Society of Nephrology Kidney Week 2026
IgA nephropathysource ↗
▲PublicationPovetaciceptFiledPresentation
Phase 3 RAINIER results for povetacicept published in the New England Journal of Medicine
IgA nephropathysource ↗
●Management ChangeCorporate
Daniel Brennan appointed to Vertex Board of Directors as independent director
▲Interim Efficacy DataAlyftrekApprovedClinical Data
Interim data show recovery of exocrine pancreatic function and PERT independence in children ages 2 to 5
Cystic Fibrosissource ↗
▲Late-BreakerAlyftrekApprovedPresentation
ALYFTREK interim data on exocrine pancreatic function presented as late breaker poster at NACFC
Cystic Fibrosissource ↗
●Poster PresentationAlyftrekApprovedPresentation
Additional abstracts on CFTR modulators presented at NACFC
cystic fibrosissource ↗
▲Late-BreakerAlyftrekApprovedPresentation
Late breaker poster of interim ALYFTREK data on exocrine pancreatic function in children 2-5 years presented at NACFC
cystic fibrosissource ↗
▲Late-BreakerAlyftrekApprovedPresentation
Late breaker poster at NACFC on ALYFTREK interim data on exocrine pancreatic function in children 2-5 years
Cystic Fibrosissource ↗
▲Interim AnalysisAlyftrekApprovedTrial
Interim analysis of ALYFTREK in children 2-5 years showing recovery of pancreatic function
Cystic Fibrosissource ↗
Unlock the full VRTX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How VRTX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-02VX-828 Phase 1 data readout Phase 1
Unlock 14 more VRTX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
20
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma
(rank 8 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
TRIKAFTA/KAFTRIO
ALYFTREK
CASGEVY
JOURNAVX
PALSONIFY
Showing 62 of 96 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
VX-880 BiologicsNCT04786262Diabetes Mellitus, Type 1Phase 3 RECRUITING 57Dec 31, 2031
Povetacicept BiologicsNCT07204275Primary Membranous NephropathyPhase 2/3 RECRUITING 176Dec 29, 2028
Povetacicept BiologicsNCT05732402Lupus NephritisPhase 1/2 ACTIVE NOT_RECRUITING 72Mar 2, 2028
Povetacicept BiologicsNCT07501702Myasthenia Gravis, GeneralizedPhase 2 ACTIVE NOT_RECRUITING 34Mar 2, 2029
Povetacicept BiologicsNCT06564142Immunoglobulin A NephropathyNDA/BLA ACTIVE NOT_RECRUITING 1,250Jan 30, 2028
VX-147 Small MoleculesNCT05312879Proteinuric Kidney DiseasePhase 2/3 ACTIVE NOT_RECRUITING 522May 7, 2030
Suzetrigine Small MoleculesNCT06696443Diabetic Peripheral Neuropathic PainPhase 3 ACTIVE NOT_RECRUITING 2,289Jan 25, 2027
VX-993 Small MoleculesNCT06619860Diabetic Peripheral Neuropathic PainPhase 2 RECRUITING 300Apr 22, 2027
VX-272 Small MoleculesNCT07437105Cystic FibrosisPhase 1 RECRUITING 160Jun 26, 2027
VX-581 Small MoleculesNCT07813039Cystic FibrosisPhase 1 ACTIVE NOT_RECRUITING 168Oct 27, 2026
VX-407 Small MoleculesNCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2 ACTIVE NOT_RECRUITING 439Dec 31, 2027
14C-VX-407 Small MoleculesNCT07868926Autosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 1 RECRUITING 8Dec 15, 2026
VX-433 Small MoleculesNCT07584434Narcolepsy Type 1 (NT1)Phase 1 RECRUITING 118Mar 5, 2027
VX-670 RNA-Based TherapiesNCT06185764Myotonic Dystrophy Type 1 (DM1)Phase 2 ACTIVE NOT_RECRUITING 91Feb 2, 2027
CTX001 CRISPR-Based Gene Editing TherapiesMarketedNCT05329649Sickle Cell DiseaseApproved ACTIVE NOT_RECRUITING 13Jun 6, 2027
Trikafta Small MoleculesMarketedNCT05331183Cystic FibrosisApproved ACTIVE NOT_RECRUITING 3,323Apr 6, 2027
Alyftrek Small MoleculesMarketedNCT05422222Cystic FibrosisApproved ACTIVE NOT_RECRUITING 2,534Jun 30, 2030
CTX001 CRISPR-Based Gene Editing TherapiesMarketedNCT05356195Beta-ThalassemiaApproved ACTIVE NOT_RECRUITING 261Nov 14, 2027
Povetacicept BiologicsCompletedNCT05757570Idiopathic Thrombocytopenic PurpuraPhase 1/2 COMPLETED 30Aug 12, 2026
ALPN-303 Small MoleculesCompletedNCT05034484UndisclosedPhase 1 COMPLETED 72Feb 27, 2023
VX-147 Small MoleculesCompletedNCT05955872Glomerulosclerosis, Focal SegmentalPhase 2 COMPLETED 37Sep 2, 2023
Inaxaplin Small MoleculesCompletedNCT06794996Proteinuric Kidney DiseasePhase 2 COMPLETED 42Jul 20, 2026
IXP Small MoleculesCompletedNCT06529796Focal Segmental Glomerulosclerosis (FSGS)Phase 1 COMPLETED 36Dec 20, 2024
IXP Small MoleculesCompletedNCT05865171Renal ImpairmentPhase 1 COMPLETED 16Jun 12, 2024
Suzetrigine Small MoleculesMarketedNCT07378865PainApproved COMPLETED 387Aug 17, 2026
Unlock the VRTX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every VRTX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ALYFTREK cystic fibrosisPhase 32026-10-09mean FE 1: 239.7 μg/g; mean increase FE 1: 110.2 µg/g; percentage reaching threshold: 48.6%; children discontinued PERT: 18 (37.5%); mean duration PERT discontinuation: 8.6 weeks; range PERT discontinuation: 1.9 to 17.6 weeks; children not on PERT: 50%Read MoreVertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceRead More
Scroll for more · summaries link to the source press release
Unlock every VRTX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock VRTX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
WAGNER CHARLES F JROfficer (EVP, CO & FO)Sell -15,286 31,764 held$547.87 11/12/2026
Unlock the full VRTX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
TRI LOCUM PARTNERS LP 13.7 % (11.4 %) 69.48 M 132.90 K -34.14% ( -68.89 K)
Unlock every fund holding VRTX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in VRTX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see VRTX ownership
Insider and institutional ownership, quarter by quarter.

VRTX Short Interest

Shares sold short, counted twice a month.

1.9%
Short % of Float
of tradable shares sold short
4.8M
Shares Sold Short
+12.9% vs prior count
3.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Unlock VRTX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock VRTX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live VRTX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock VRTX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How VRTX ranks across every disease it competes in

Competitive Position is a premium feature
See how VRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

VRTX News

VRTX
Nov 4, 2026
VRTXConferences/Events

Vertex to Participate in Upcoming Investor Conferences

Vertex Pharmaceuticals announced participation in three upcoming investor conferences. Key executives will engage in fireside chats at the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Evercore Healthcare Conference in November and December 2026. Live webcasts of these events will be available on the company's website.

Read more →
VRTX
Nov 2, 2026
VRTXGeneral

Vertex Reports Third Quarter 2026 Financial Results

Vertex Pharmaceuticals reported a strong third quarter for 2026, achieving total revenue of $3.44 billion, a 12% increase from the previous year. The company raised its full-year revenue guidance to between $13.15 billion and $13.25 billion. Key drivers included robust performance in cystic fibrosis therapies and the successful acquisition of Crinetics Pharmaceuticals. However, GAAP net income saw a decline due to acquisition-related expenses.

Read more →
VRTX
Oct 23, 2026
VRTXPhases

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Vertex Pharmaceuticals announced positive Phase 3 RAINIER results for povetacicept in IgA nephropathy, published in NEJM and presented at ASN Kidney Week 2026. The trial achieved a 52% reduction in proteinuria at Week 36, meeting both primary and secondary endpoints. The FDA's PDUFA date for potential accelerated approval is set for November 30, 2026.

Read more →
VRTX
Oct 20, 2026
VRTXGeneral

Vertex Appoints Daniel Brennan to its Board of Directors

Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors. Brennan, with over 35 years of finance experience, previously served as CFO at Boston Scientific. His financial leadership is expected to support Vertex's growth and innovation efforts. The Board size increased from 10 to 11 members with this appointment.

Read more →
VRTX
Oct 9, 2026
VRTXConferences/Events

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Pharmaceuticals announced promising interim data from the ALYFTREK® study, which focuses on children aged 2 to 5 with cystic fibrosis. The data indicates that some children have shown recovery of exocrine pancreatic function, allowing them to stop pancreatic enzyme replacement therapy. This marks a significant advancement in the treatment of cystic fibrosis.

Read more →
VRTX
Oct 7, 2026
VRTXConferences/Events

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

Vertex Pharmaceuticals will announce its third quarter 2026 financial results on November 2, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing investors with insights into the company's performance. Access details for the call are provided for both U.S. and international participants.

Read more →
VRTX
Sep 22, 2026
VRTXPhases

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Vertex Pharmaceuticals announced positive results from the Phase 2b AMPLIFIED study of inaxaplin for APOL1-mediated kidney disease. The study demonstrated significant reductions in urine albumin to creatinine ratio (UACR) in patients with modest proteinuria and those with type 2 diabetes. Vertex has completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim analysis results expected in early 2027, which could support accelerated approval in the U.S.

Read more →
VRTX
Sep 15, 2026
VRTXGeneral

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals has teamed up with champion skier Lindsey Vonn to promote JOURNAVX, a non-opioid medication approved for treating moderate-to-severe acute pain. This partnership aims to raise awareness about the first new class of pain medicine in over two decades. JOURNAVX was approved by the FDA in January 2025.

Read more →
VRTX
Sep 1, 2026
VRTXGeneral

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals has successfully completed its acquisition of Crinetics Pharmaceuticals, a company specializing in therapeutics for endocrine diseases. This acquisition is part of Vertex's strategy to diversify and grow its portfolio. Additionally, the company has expanded its executive leadership team to better support its ongoing development and expansion efforts.

Read more →
VRTX
Aug 26, 2026
VRTXConferences/Events

Vertex to Participate in Upcoming September Investor Conferences

Vertex Pharmaceuticals has announced its participation in four upcoming investor conferences, highlighting its commitment to investor engagement. Senior Vice President Susie Lisa and Executive Director Manisha Pai will lead discussions at notable events, including the Wells Fargo 21st Annual Healthcare Conference. This proactive approach reflects the company's transparency and confidence in its future.

Read more →
VRTX
Aug 3, 2026
VRTXGeneral

Vertex Reports Second Quarter 2026 Financial Results

Vertex Pharmaceuticals reported strong financial results for Q2 2026, highlighting significant revenue growth in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain. The company also updated its full-year revenue guidance positively. Additionally, the pending acquisition of Crinetics will expand its focus to rare endocrine diseases.

Read more →
VRTX
Jul 7, 2026
VRTXGeneral

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Vertex Pharmaceuticals is set to announce its financial results for the second quarter of 2026 on August 3rd. This announcement is part of the company's regular financial reporting schedule. Details regarding the performance and outlook will likely be discussed during the announcement.

Read more →
VRTX
Jul 6, 2026
VRTXGeneral

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals. The acquisition aims to enhance Vertex's portfolio and capabilities in the biopharmaceutical sector. Further details regarding the financial aspects and strategic implications of the acquisition have yet to be disclosed.

Read more →
VRTX
Jul 1, 2026
VRTXFDA Updates
▲ +6%on this newsshared move

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Vertex has received FDA approval for the expanded use of CASGEVY® in treating individuals aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. This approval represents a significant milestone in providing effective treatment options for these conditions. The decision is expected to enhance patient care and outcomes.

Read more →
VRTX
Jun 11, 2026
VRTXConferences/Events

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex Pharmaceuticals presented new data on CASGEVY® at the European Hematology Association Congress. This included the first European presentation of data in children aged 5-11. Additionally, the company announced further global regulatory submissions related to CASGEVY®.

Read more →
VRTX
Jun 5, 2026
VRTXConferences/Events

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex Pharmaceuticals presented new data on ALYFTREK® at the European Cystic Fibrosis Conference. The details of the findings were not disclosed in the article. The presentation is expected to contribute to ongoing discussions about cystic fibrosis treatments.

Read more →
VRTX
Jun 3, 2026
VRTXConferences/Events

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 10. This event is a significant platform for the company to engage with investors and discuss its strategic initiatives. Further details about the participation are yet to be disclosed.

Read more →
VRTX
Jun 1, 2026
VRTXFDA Updates

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals announced that the U.S. FDA has accepted its Biologics License Application for Povetacicept, aimed at treating IgA Nephropathy. This acceptance is a crucial step towards potential accelerated approval, which may enhance patient access to this innovative therapy. The company is optimistic about the drug's prospects in addressing this condition.

Read more →
VRTX
May 12, 2026
VRTXConferences/Events

Vertex to Participate in Upcoming May 2026 Investor Conferences

Vertex Pharmaceuticals announced its participation in two upcoming investor conferences in May 2026. The company is known for its innovative therapies for serious diseases and has a strong clinical pipeline. Vertex has been recognized as a top employer, reflecting its commitment to workplace excellence.

Read more →
VRTX
May 11, 2026
VRTXConferences/Events

Vertex to Participate in Upcoming May Investor Conferences

Vertex Pharmaceuticals is set to participate in several investor conferences in May. The details regarding the specific conferences and the topics to be discussed have not been disclosed. This participation may provide insights into the company's future plans and developments.

Read more →

About Vertex Pharmaceuticals Incorporated

Boston, MA 6,400 employees vrtx.com
Headquarters50 NORTHERN AVENUE, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE
Trade the next VRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime